Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Abbott Presents Positive Results From Phase 2 "Pilot" Study Of An Interferon-Free Combination Regimen For The Treatment Of Hepatitis C
Pharmaceutical Online
Saturday, April 21, 2012 - 1:03pm
tags:
Abbott Laboratories, ABT-072, ABT-450, hepatitis C
Eli Lilly & Co. First Quarter Earnings Sneak Peek
Wall St. Cheat Sheet
Saturday, April 21, 2012 - 1:00pm
tags:
Eli Lilly, earnings
Celebrate the Hep C Wins, for Now
Motley Fool
Saturday, April 21, 2012 - 12:26pm
tags:
hepatitis C, Gilead Sciences, GS-7977, daclatasvir, Bristol-Myers Squibb, Abbott Laboratories, Vertex Pharmaceuticals, Incivek
Cure Worms, Make Money
Motley Fool
Saturday, April 21, 2012 - 12:24pm
tags:
GSK, tropical diseases, Novartis, Pfizer, Abbott Laboratories, JNJ
Danone hikes Pfizer unit bid
Yahoo/Investor's Business Daily
Saturday, April 21, 2012 - 12:21pm
tags:
Danone, Pfizer
For Sale, Just Not at That Price
Motley Fool
Saturday, April 21, 2012 - 12:20pm
tags:
Human Genome Sciences, GSK, M&A
Patent Challenge for Auxilium Pharma
Yahoo/Zacks
Saturday, April 21, 2012 - 12:19pm
tags:
Auxilium, Watson Pharmaceuticals, Testim, generics
5 Biotech Stocks That Could Soar On New Hepatitis C Drugs
Seeking Alpha
Saturday, April 21, 2012 - 12:17pm
tags:
Vertex, Incivek, ABT-072, ABT-450, Abbott Laboratories, Achillion, ACH-1625, ACH-2684, ACH-2928, ACH-3102, TMC435, JNJ, GSK, hepatitis C
Checking the Quality of Sequenom's Intangibles
Motley Fool
Saturday, April 21, 2012 - 12:05pm
tags:
Sequenom
Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
Yahoo/Globe NewsWire
Saturday, April 21, 2012 - 12:05pm
tags:
Achillion, ACH-1625, ACH-3102, ACH-2928, hepatitis C
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
Yahoo/PR NewsWire
Saturday, April 21, 2012 - 12:03pm
tags:
Chelsea Therapeutics, lawsuits
Human Genome Sciences First Quarter Earnings Sneak Peek
Wall St. Cheat Sheet
Saturday, April 21, 2012 - 12:02pm
tags:
Human Genome Sciences, earnings
PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
Yahoo/PR NewsWire
Saturday, April 21, 2012 - 12:01pm
tags:
Prolor
PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
Yahoo/Globe NewsWire
Saturday, April 21, 2012 - 11:54am
tags:
PolyMedix, PMX-30063, antibiotics
Holzer Holzer & Fistel, LLC Announces Investigation into ViroPharma Incorporated
Yahoo/BusinessWire
Saturday, April 21, 2012 - 11:52am
tags:
ViroPharma, lawsuits
Partner Up or Get Passed Up
Motley Fool
Saturday, April 21, 2012 - 11:51am
tags:
GS-7977, Vertex Pharmaceuticals, hepatitis C, Roche, Bristol-Myers Squibb, Merck, Gilead Sciences, JNJ
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases
Yahoo/BusinessWire
Saturday, April 21, 2012 - 11:49am
tags:
Biogen, Tysabri, Fampyra, BG-12, multiple sclerosis, amyotrophic lateral sclerosis, DAC HYP
3 Hot Biotech Stocks To Consider For New Obesity Drugs
Seeking Alpha
Saturday, April 21, 2012 - 11:46am
tags:
Arena Pharmaceuticals, lorcaserin, Vivus, Qnexa, Orexigen, Contrave
Dendreon Is Not A Great Short
Seeking Alpha
Saturday, April 21, 2012 - 11:42am
tags:
Dendreon
Playing the Immune System for Profit
Motley Fool
Saturday, April 21, 2012 - 11:41am
tags:
immune system

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.